Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Latest Articles
Corporate Profile
Young scientists realize their potential at our company
Three international postdocs explain what they are focusing their research on and why they chose Boehringer Ingelheim.
Corporate Profile
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Corporate Profile
Career tips from our Global Head of HR
Sven Sommerlatte explains how important it is to reflect on the personal career strategy.
Links
Discover our global career opportunities
We offer a wide range of career development opportunities in over 140 affiliates worldwide. Click "Read more" to check out the local career sites.
Working at Boehringer Ingelheim
As a research-driven pharmaceutical company Boehringer Ingelheim strives to improve health of people and animals everywhere in the world.
About us
Financial Highlights 2021
Net sales, Research and Development expenditures, Operating Income and Personnel Capacity: Boehringer Ingelheim grows
Annual Report 2021: Tomorrow
Tomorrow holds great opportunities for more progress, more sustainability, and better health. Read inspiring stories on our understanding of a healthier future in our annual report.
Downloads
Boehringer Ingelheim Corporate Factsheet
Find all important information about our company at a glance.
Company Profile Boehringer Ingelheim
Value through Innovation
Major consolidated companies
Overview of selected consolidated companies
Related Press Releases
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
April 05, 2022